ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/anti-ERBB3-monoclonal-antibody
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/anti-ERBB3-monoclonal-antibody
3
trial(s) found.
NCT06170190
Advanced
Phase 1 / Phase 2
Recruiting
A Multicentre, Open-label, Phase 1/2 Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours (
CIBI133A101
)
anti-ERBB3 monoclonal antibody
Solid tumour
NSW
2170 - Liverpool - Liverpool Hospital
NCT05910827
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers (
HMBD-001-103
)
anti-EGFR monoclonal antibody
anti-ERBB3 monoclonal antibody,third generation
taxane
Squamous non-small-cell lung cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05919537
Advanced
Phase 1
Active not recruiting
A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations (
HMBD-001-102
)
anti-ERBB3 monoclonal antibody,third generation
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Active not recruiting (1)
Recruitment Country and State
NSW (3)
QLD (2)
SA (2)
VIC (2)
WA (2)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (2)
Trial Type
Advanced (3)
Cancer Therapy Class
ERBB3
100%
EGFR
33%
Facility
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
6009 - Nedlands - Linear Clinical Research (2)
2170 - Liverpool - Liverpool Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Squamous non-small-cell lung cancer
Gastrointestinal cancer
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy